Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7726 to 7740 of 8213 results

  1. How we develop NICE guidelines

    The guidance development timeline

  2. About shared decision making

    Information and benefits about shared decision making. Includes links to patient decision aids.

  3. Measuring the use of NICE guidance

    NICE works with partners including Public Health England, NHS England and NHS Improvement to assess services and support innovation and best practice.

  4. Payments and expenses

    Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.

  5. Your role as a NICE committee member

    Home Get involved Our committees...

  6. People need support to keep weight off after treatment ends

    People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.

  7. Patients to receive medicines 3 to 6 months faster under 10-Year Health Plan

    NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

  8. NICE Advice service

    NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,

  9. How to use quality standards

    How providers and commissioners can use quality standards to improve the quality of care

  10. Science policy and methods projects

    Science policy projects with NICE.

  11. Permission to use NICE content for artificial intelligence (AI) purposes

    Permission form to use NICE content for artificial intelligence (AI) purposes.

  12. What NICE does

    We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  13. Terms and conditions

    Home {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/","name":"Home"}}]}

  14. Final decision on cerliponase alfa for Batten disease treatment confirmed

    In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.

  15. Life sciences: how to get your product to market

    NICE Advice works closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.